Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity
- 1 July 1995
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 1 (7) , 649-653
- https://doi.org/10.1038/nm0795-649
Abstract
Cytotoxic T lymphocytes (CTLs) kill neoplastic or virally infected cells after recognizing on their surface antigenic peptides bound to major histocompatibility complex class I molecules. These peptides are derived from antigens that are degraded in the cytosol of the affected cell. Because exogenous proteins cannot enter the cytosol, immunizations with killed pathogens or their proteins do not generally elicit CTLs. However, antigens that are internalized into phagocytic cells can enter the cytosol and be processed for class I presentation. Here we show that immunization with a purified antigen on an avidly phagocytized particle primes CTLs, which in turn protect animals from subsequent challenge with tumours transfected with the antigen gene. Interestingly, these animals also become immune to other antigens expressed by the tumour. This approach could be exploited to develop tumour and viral vaccines.Keywords
This publication has 25 references indexed in Scilit:
- Direct analysis of tumor-associated peptide antigensCurrent Opinion in Immunology, 1994
- Presentation of exogenous antigens by macrophages: analysis of major histocompatibility complex class I and II presentation and regulation by cytokinesEuropean Journal of Immunology, 1994
- A new look for the 1990sNature, 1994
- Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor AntigensScience, 1994
- Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral ProteinScience, 1993
- Phagocytic processing of bacterial antigens for class I MHC presentation to T cellsNature, 1993
- Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo.The Journal of Experimental Medicine, 1990
- CD8+ T lymphocytes in intracellular microbial infectionsImmunology Today, 1988
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Introduction of soluble protein into the class I pathway of antigen processing and presentationCell, 1988